Gland Pharma Q4 FY26 profit jumps 97%, sales up 22%

Key Q4 takeaway for investors

Gland Pharma reported a sharp year-on-year rise in consolidated profit for the quarter ended March 2026 (Q4 FY26), supported by higher net sales and a jump in operating profitability. Consolidated net profit rose 96.62% to Rs 366.7 crore, compared with Rs 186.54 crore in Q4 FY25. Net sales increased 22.31% to Rs 1,742.80 crore from Rs 1,424.91 crore a year earlier. Profit before tax (PBT) for the quarter stood at Rs 505.79 crore, up 75.42% from Rs 288.33 crore in Q4 FY25. Consolidated EBITDA for the March 2026 quarter was Rs 513 crore, up 48% year-on-year, with an EBITDA margin of 29%.

Q4 FY26 numbers: profit, sales and margins

The Q4 performance was driven by a stronger revenue base and improved operating earnings. While the company reported higher profit and sales, the margin disclosure in the update pointed to EBITDA margin at 29% for the quarter. On the cost side, the broader financial snapshot also highlighted that, for the year ending March 31, 2025, the company spent less than 1% of operating revenues towards interest expenses and 24.95% towards employee cost. In quarterly data provided alongside the update, Q3 FY26 (ended December 2025) PAT was shown at Rs 261.48 crore, with total income of Rs 1,758.54 crore and EBIT of Rs 366.06 crore. That context matters because it frames Q4 as a quarter where bottom-line growth accelerated further versus the year-ago period.

Regional sales highlights mentioned in the update

Gland Pharma’s disclosure included a brief split for some markets in Q4 FY26. Sales in Canada, Australia and New Zealand were Rs 58.8 crore, down 2% year-on-year. Sales in India were Rs 67 crore, up 28% year-on-year. The update did not provide a complete geography mix for the quarter, but it flagged that some markets moved in different directions. The information also fits with the company’s broader positioning as a global sterile injectables player with meaningful overseas exposure.

Full-year FY26: net profit up 47%, sales up 14.5%

For the full year ended March 2026 (FY26), consolidated net profit rose 47.07% to Rs 1,027.32 crore from Rs 698.53 crore in FY25. Full-year sales increased 14.50% to Rs 6,430.65 crore from Rs 5,616.50 crore in FY25. The full-year print shows profit growing faster than sales, consistent with the quarterly narrative of improved profitability. The article data did not specify one-off items for FY26, so the reported growth is presented on the stated consolidated numbers.

Stock market reaction: shares end lower

Despite the earnings growth, Gland Pharma shares fell 1.80% to end at Rs 1,861 on the BSE on the day referenced in the update. The move highlights that market reaction can diverge from headline profit growth, depending on expectations and other factors the market may have been pricing in. Separately, a valuation snapshot in the provided text referenced a price of Rs 1,688.70, at which the stock traded at 35.26 times trailing twelve-month earnings, 2.91 times book value, and 18.34 times EV/EBITDA. Since these two prices differ, they appear to refer to different points in time.

Q3 FY26 context also included in the material

The dataset also carried Q3 FY26 performance references from multiple sources. One disclosure cited consolidated revenue from operations of Rs 1,695.36 crore for Q3 FY26, up 22.49% year-on-year from Rs 1,384.05 crore. It also cited net profit for Q3 FY26 at Rs 279.06 crore, up 36.30% year-on-year. A Reuters report dated Jan. 28 added that the company reported a consolidated net profit of 2.61 billion rupees (Rs 261 crore) for the quarter ended December 31, versus 2.05 billion rupees (Rs 205 crore) a year earlier, and revenue from operations rose 22.5% to 16.95 billion rupees (Rs 1,695 crore). The Reuters copy also said U.S. sales, which make up more than half of the total, rose 19%, while the Europe business posted a 54% rise.

What the Q4 margin and PBT say about operating performance

For Q4 FY26, the company’s EBITDA rose to Rs 513 crore and the EBITDA margin was disclosed at 29%. PBT growth of 75.42% year-on-year to Rs 505.79 crore indicates that profitability improved materially versus the year-ago quarter. These figures are important for investors tracking how much of the earnings growth is supported by operating performance rather than only revenue growth. The Q4 disclosures did not provide a detailed breakdown of other income or finance costs for the quarter, but the combination of higher sales, higher EBITDA, and higher PBT points to a broad-based improvement on reported measures.

Summary table of reported figures

Why the FY26 print matters for tracking the business

FY26 numbers show a year where profit grew faster than sales on consolidated reporting. Net profit for the year rose to Rs 1,027.32 crore on sales of Rs 6,430.65 crore. Investors following the company’s progress across quarters can also map Q4 results against the Q3 revenue run-rate near Rs 1,695 crore, as cited in the provided material. The text also noted the company’s market capitalisation at Rs 27,679 crore and that it is majority-owned by Fosun Pharma with a 51.83% stake. These are relevant details for readers tracking ownership and market positioning.

Conclusion

Gland Pharma’s Q4 FY26 results showed strong year-on-year growth in profit, sales, EBITDA, and PBT on a consolidated basis, with FY26 also closing higher on both revenue and net profit. The stock, however, ended the referenced session down 1.8% on the BSE. Investors will likely track subsequent quarterly updates for sustained sales momentum across geographies and consistency in margins, using the reported FY26 base as a reference point.